Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression.

Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.